In conclusion, we for the first time reveal the positive predictive value of ROS1 mutation, characterized with increased tumor antigenicity and gene damage, for ICI therapy in melanoma, which is distinct from the well-established role of ROS1 rearrangement for targeted therapy in NSCLC. This evidence concerns the gene ROS1 and neoplasm.